Sales of Bifurcation Lesion Devices Are Expected to Increase at a CAGR of 6% by 2033

The global bifurcation lesions market was valued at US$ 2.25 billion in 2022. Global sales of bifurcation lesion devices are expected to increase at a CAGR of 6% and reach a market valuation of US$ 4.26 billion by the end of 2033.

Rising demand for the treatment of coronary bifurcation lesions is due to the availability of treatments specifically designed to treat lesions near the coronary bifurcation, their greater awareness about the treatment procedures, and an increase in percutaneous coronary intervention operations.

To remain 'ahead' of your competitors, request for a sample:
https://www.factmr.com/connectus/sample?flag=S&rep_id=7963

Key Takeaways of Bifurcation Lesions Market

• The bifurcation lesions market is experiencing growth due to an increasing prevalence of coronary artery disease and a rising demand for minimally invasive treatment options.
• Bifurcation lesions occur when there is a blockage or narrowing in the branch point of a blood vessel, particularly in the coronary arteries. These lesions pose a significant challenge in interventional cardiology and require specialized techniques for effective treatment.
• Minimally invasive procedures, such as percutaneous coronary intervention (PCI), are the preferred treatment option for bifurcation lesions. PCI involves the use of stents to open up and restore blood flow in the affected arteries.
• Advanced technologies and techniques have been developed specifically for bifurcation lesion treatment, including dedicated bifurcation stents, drug-eluting stents, and the use of imaging and guidance systems to optimize stent placement.
• The market is witnessing a shift towards the use of drug-eluting stents, which are coated with medications that help prevent restenosis (re-narrowing) of the blood vessels after the procedure. These stents have shown improved outcomes and reduced rates of repeat procedures compared to bare-metal stents.

Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=7963

Competitive Landscape

Key players in the global bifurcation lesions market are developing improved solutions by employing innovative technologies. They are also focusing on collaborations and purchases to improve their product line and generate more income.
• On June 10, 2019, eight interventional product categories underwent new group purchasing product agreements with Premier owing to Cordis, a Cardinal Health Company.
• A brand-new, innovative radial to periphery self-expanding stent was introduced by Terumo in September 2019. The corporation benefited from the introduction of this new product by growing its product line and increasing income.
• Abbott announced the introduction of Ultreon 1.0 Software powered by Al, a coronary imaging platform, in Europe in April 2021. The software's goal is to increase calcium-based blockage identification and artery diameter measurement while coronary stenting operations.

Key Companies Profiled:
• Abbott
• Boston Scientific Corporation
• C. R. Bard, Inc.
• Cardinal Health
• Johnson& Johnson Services, Inc.
• Medtronic
• Spectranetics
• Terumo Medical Corporation

For in-depth competitive analysis, Buy Now:
https://www.factmr.com/checkout/7963

Key Segments of Bifurcation Lesions Industry Research

• By Type :
o One-stent Bifurcation Lesions
o Two-stent Bifurcation Lesions

• By Application :
o Coronary Vascular
o Peripheral Vascular

Key Questions Covered in the Bifurcation Lesions Market Report

• What is the projected value of the Bifurcation Lesions factors Industry in 2023?
• At what rate will the global Bifurcation Lesions factors market size grow until 2033?
• Which are the factors hampering the growth of Bifurcation Lesions factors?
• Which region is expected to lead in the global Bifurcation Lesions factors market By 2033?
• Which are the factors driving the Bifurcation Lesions factors Industry during the forecast period?
• What is the expected market value of the Bifurcation Lesions factors market during the forecast period?

Regional Analysis For Bifurcation Lesions Market:

• APAC (Japan, China, South Korea, Australia, India, and the rest of APAC; the rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
• North America (USA, Canada and Mexico)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (Saudi Arabia, United Arab Emirates, South Africa)

11140 Rockville Pike, Suite 400, Rockville, MD 20852, United States

Market research and consulting agency with a difference! That's why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range - from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we'll be an able research partner.

This release was published on openPR.